Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892397 · ClinicalTrials.gov registry record · NA
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
A NA study of Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 9
- Study locations
NCT01892397: Active NA study of Brain Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01892397 is a NA study of Brain Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01892397, a NA study of Brain Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses an experimental device called Optune. Optune is "experimental" because it has not been approved by the U.S. Food and Drug Administration (FDA) for this type of tumor, although it has been approved for a different type of brain tumor.
Primary Outcome
From the treatment start date to the date of the first observation of progressive disease (including clinical progression) or death due to any cause. Patients not known to be progression-free at 6 months will be considered treatment failures.
Conditions Studied
Interventions
- DEVICE Optune (NovoTTF-100A)
Study Locations (9)
New York
- Memorial Sloan Kettering Cancer Center at Commack - Commack
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University - New York
California
- Cedars-Sinai Medical Center - Los Angeles
Colorado
- University of Colorado - Denver
Florida
- University of Miami - Miami
New Jersey
- Memorial Sloan Kettering Cancer Center - Basking Ridge
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT01892397 still lists
NCT01892397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 1 intervention - of which Optune (NovoTTF-100A) is the first listed.
NCT01892397 lists 9 locations in 6 states (New York, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT01892397 about?
NCT01892397 is a clinical study titled "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma". The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses a...
What is the current status of trial NCT01892397?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT01892397 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT01892397?
The interventions under investigation include: Optune (NovoTTF-100A) (DEVICE).
Who is sponsoring clinical trial NCT01892397?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01892397 being conducted?
This trial has 9 study locations across California, Colorado, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01892397's enrollment target sits among peer trials
6 47th of 47 higher than 1 of 47 other Brain Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
RECRUITING · NA
-
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
RECRUITING · NA
-
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
RECRUITING · NA
-
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia